The British Journal of Psychiatry · 2020 · 53 citations · 0 references
PharmacyPharmacologyPsychiatryInfectious Disease PharmacotherapyPsychiatric PharmacotherapyPsychopharmacologyAntidepressant TherapyAntipsychotic PharmacotherapyAntipsychotic TherapyAntiviral PharmacotherapyAntiviral TherapyTreatment Of Mental DisordersAntipsychotic Medication UseAntipsychotic SafetyAntiviral TherapeuticsAntiviral TreatmentPsychiatric Medication SafetyRecognition Of Psychiatric Symptoms
Many psychiatric patients have been infected with COVID-19, and patients with COVID-19 may develop psychiatric symptoms after treatment with antiviral drugs. Given the tolerability and minimal P450 interactions, antidepressants (i.e., citalopram, escitalopram etc.), antipsychotics (i.e., olanzapine) and valproate can be considered to be safe in combination with antiviral drugs.